In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Can Do More To Facilitate Approval Efficiency – CSDD

This article was originally published in Pharmaceutical Approvals Monthly

You may also be interested in...



Pursuit Of R&D Efficiency Continues As Regulatory Options Expand In 2013 – Tufts CSDD

Cutting non-core procedures – such as those supporting exploratory endpoints – from study budgets could save the industry $6 billion a year in drug development costs, the Tufts Center for the Study of Drug Development suggests in its 2013 industry outlook report.

Innovation Pays: Priority Drugs Drove Novel 2011 Approvals To New Heights

The new molecular entity and novel biologic class of 2011 isn’t just the largest since 2004 – CDER also posted near-perfect on-time review performance while maintaining healthy rates of first-cycle approvals and a low 15 month average time to approval, thanks to a high level of innovation in the novel product candidates.

PDUFA Word Association: Consumer Advocates Complain About Lack Of "Safety" In Commitment Letter

FDA’s Oct. 24 public meeting on the renewal of its drug user fee program demonstrated just how strong a position the agency is in regarding the renewal of the Rx part of the “UFA” legislation – most of the complaints were semantic, quite literally.

Topics

UsernamePublicRestriction

Register

PS004928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel